Key result
β-blockers show potential for repurposing in non-cardiovascular diseases, with retrospective evidence suggesting they may decrease mortality in sepsis and potentially benefit cancer treatment.
Why the study?
Do beta-blockers improve survival outcomes in patients with non-cardiovascular diseases such as sepsis and cancer?
Do beta-blockers improve survival outcomes in patients with non-cardiovascular diseases such as sepsis and cancer?
Answers are grounded in this paper and cite their sources.
This editorial highlights the potential of repurposing beta-blockers for non-cardiovascular diseases like sepsis and cancer, while emphasizing the need for large-scale prospective studies to confirm efficacy.
Editorial on the Research Topic Repurposing -blockers for non-cardiovascular diseases -Blockers are a class of drugs that have been approved by the FDA for the treatment of cardiovascular diseases. However, Some -blockers have been found to be effective in treating other disorders beyond the cardiovascular system, such as CNS conditions, diabetes, cancer, and organ toxicities Furthermore, -blockers are proposed to act as immunomodulators due to the role of -adrenergic receptors in immunity Regarding the protection against organ toxicity, non-selective -blockers, such as carvedilol and propranolol, have been found to protect against renal toxicity The effects of -blockers on diseases outside of the cardiovascular system may not necessarily be related to their -blocking activity. This issue compiles preclinical and clinical studies, along with a review article, on the use of blockers for non-cardiovascular diseases. These studies provide evidence for repurposing these FDA-approved drugs for other diseases and identifying new mechanisms for their use beyond -adrenergic receptor blockade.
No takes yet. Share an insight, caveat, or question.
Shahid et al. (2024) conducted an editorial in Non-cardiovascular diseases (sepsis, cancer). β-blockers was evaluated. β-blockers show potential for repurposing in non-cardiovascular diseases, with retrospective evidence suggesting they may decrease mortality in sepsis and potentially benefit cancer treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: